RPL17 Antibody

What is RPL17 and what cellular functions does it perform?

RPL17 (Ribosomal Protein L17) is a component of the 60S ribosomal subunit with a molecular weight of approximately 21-24 kDa . It functions primarily in ribosome biogenesis and protein synthesis but has also been implicated in extra-ribosomal functions. RPL17 is expressed in multiple tissues including pancreas, lung, colon, cystic duct, gallbladder, kidney, and liver . The protein demonstrates variable expression patterns across different cell types, with notably high expression in several pancreatic tumor cell lines including HPAF, COLO 357, and Capan-1 . Beyond its canonical role in translation, RPL17 has been identified as a vascular smooth muscle cell (VSMC) growth inhibitor with tumor suppressor-like properties .

How do I select the appropriate RPL17 antibody for my research application?

Selection of an RPL17 antibody should be based on several experimental considerations:

• Target epitope location: Consider whether your research requires antibodies targeting specific regions such as N-terminal, C-terminal, or internal domains. For instance, antibodies like ABIN653848 target the C-terminal region (AA 156-184) of human RPL17 .

• Application compatibility: Verify that the antibody has been validated for your intended application:

  Application	Common Antibody Options	Validation Requirements
  Western Blot (WB)	DF3699, ABIN653848	Protein band at 21-24 kDa
  Immunohistochemistry (IHC)	DF3699, ABIN653848	Tissue-specific expression pattern
  Immunofluorescence (IF/ICC)	DF3699	Subcellular localization

• Species reactivity: Ensure compatibility with your experimental model. For example, DF3699 antibody reacts with human, mouse, and rat samples with predicted reactivity in zebrafish, bovine, horse, sheep, rabbit, dog, and Xenopus models .

• Clonality considerations: Determine whether a polyclonal antibody (providing multiple epitope recognition) or monoclonal antibody (offering higher specificity) better suits your experimental needs.

What are the primary applications for RPL17 antibodies in ribosome research?

RPL17 antibodies serve as valuable tools for investigating ribosome biogenesis and rRNA processing mechanisms. Research applications include:

• Pre-rRNA processing analysis: RPL17 antibodies can help detect alterations in pre-rRNA ratios following Rpl17 knockdown, revealing impaired processing in internal transcribed spacers (ITS1 and ITS2) .

• Ribosomal subunit assembly studies: RPL17 is required for processing 32S pre-rRNA to 28S and 5.8S precursors during pre-60S subunit assembly in mouse cells, mirroring the function of yeast L17 .

• Exonuclease progression investigation: RPL17 may function as a steric inhibitor limiting 5′ exonuclease progression. Antibodies can help analyze how depletion affects Xrn2 activity in mammalian complexes, similar to Rat1 in yeast models .

• Ribosomal protein localization: Immunofluorescence with RPL17 antibodies enables visualization of ribosomal protein distribution within cellular compartments.

How can RPL17 antibodies be utilized to investigate the protein's role as a VSMC growth inhibitor?

RPL17 has been identified as a vascular smooth muscle cell (VSMC) growth inhibitor with tumor suppressor-like properties . Researchers can employ RPL17 antibodies to:

• Quantify expression levels: Western blot analysis using RPL17 antibodies can reveal expression differences between experimental models. For example, RpL17 protein expression was approximately 2.5-fold higher in C3H/F mouse aortic smooth muscle cells (MASMC) compared to SJL MASMC, correlating with differences in proliferation rates .

• Analyze tissue-specific expression patterns: Immunohistochemistry with RPL17 antibodies can detect expression changes following interventions. After partial carotid ligation in SJL mice, researchers observed decreased RpL17 expression in the intima and media, corresponding with increased proliferating cell counts .

• Investigate signaling pathway interactions: Co-immunoprecipitation with RPL17 antibodies can identify interaction partners potentially involved in growth inhibition pathways.

• Monitor therapeutic interventions: As RPL17 represents a potential therapeutic target to limit carotid intima-media thickening, antibodies can assess changes in expression following experimental treatments .

What experimental considerations should be made when studying RPL17's extra-ribosomal functions?

When investigating RPL17's non-canonical roles:

• Cellular compartment isolation: Ensure proper subcellular fractionation to distinguish ribosome-associated from free-pool RPL17.

• Expression level control: Consider that both overexpression and knockdown approaches may disrupt ribosome biogenesis, potentially creating secondary effects that complicate interpretation.

• Specificity verification: Use multiple antibody clones or epitope tags to confirm findings are specific to RPL17 and not cross-reactive with other ribosomal proteins.

• Model system selection: Differences exist between species, as evidenced by functional parallels between mammalian Rpl17 and yeast L17, but with variations in pre-rRNA processing patterns .

• Temporal dynamics: RPL17 may have developmental or cell-cycle dependent functions requiring time-course experiments with synchronized cells.

How do mutations or altered expression of RPL17 impact ribosome biogenesis and cellular phenotypes?

Altered RPL17 expression creates distinct molecular signatures that can be studied using antibody-based approaches:

• Pre-rRNA processing defects: Rpl17 knockdown impairs pre-rRNA processing, particularly affecting ratios of pre-rRNAs with lowered levels of 34S and 20S pre-rRNAs generated through cleavage at site 2c in ITS1, while 18SE and 36S pre-rRNAs (requiring site 2b cleavage) show minimal effects .

• Degradation product accumulation: Northern hybridizations reveal elevated amounts of pre-rRNA degradation products after Rpl17 knockdown, indicating active turnover of 32S pre-rRNA in pre-60S complexes .

• Exonuclease interaction: Primer extensions show decreased 32S C fraction when both Xrn2 and Rpl17 are depleted, suggesting RPL17 may function similarly to yeast L17 as a steric inhibitor of exonuclease progression .

• Proliferation impacts: In vascular smooth muscle cells, reduced RPL17 expression correlates with increased proliferation. Following pluronic gel delivery of RpL17 siRNA to C3H/F carotid arteries, researchers observed an 8-fold increase in proliferating cell numbers .

What optimization steps should be taken for Western blot analysis with RPL17 antibodies?

For optimal Western blot results with RPL17 antibodies:

• Sample preparation:

  • Include protease inhibitors to prevent degradation of the 21-24 kDa RPL17 protein

  • For ribosomal fraction enrichment, consider sucrose gradient centrifugation

  • Ensure complete protein denaturation using appropriate buffer systems

• Gel selection and transfer:

  • Use 12-15% polyacrylamide gels for optimal resolution of the 21-24 kDa target

  • Employ semi-dry transfer for smaller proteins like RPL17

  • Consider PVDF membranes for enhanced protein retention

• Antibody dilution optimization:

  • Start with manufacturer's recommended dilutions (typically 1:1000-1:2000)

  • Perform titration experiments to determine optimal signal-to-noise ratio

  • For DF3699 and similar antibodies, determine optimal dilutions experimentally based on sample type

• Detection strategies:

  • Use enhanced chemiluminescence for standard detection

  • Consider fluorescent secondary antibodies for multiplex detection with other ribosomal markers

  • Include appropriate molecular weight markers to confirm the expected 21-24 kDa band

What controls should be included in experiments using RPL17 antibodies?

Proper experimental controls are essential for reliable RPL17 antibody-based research:

• Positive controls:

  • Cell lines with confirmed RPL17 expression (e.g., pancreatic tumor cell lines HPAF, COLO 357, and Capan-1)

  • Tissues with known high expression (pancreas, lung, kidney, liver)

  • Recombinant RPL17 protein standard

• Negative controls:

  • Primary antibody omission

  • Non-specific IgG of the same species and concentration

  • RNAi-mediated knockdown samples for specificity verification

• Loading controls:

  • Total protein staining for normalization

  • Other ribosomal proteins of similar abundance but different function

  • Housekeeping proteins for whole-cell lysate normalization

• Validation approaches:

  • Multiple antibodies targeting different epitopes

  • Correlation with mRNA expression data

  • Mass spectrometry validation of immunoprecipitated samples

How can I optimize immunohistochemistry protocols for RPL17 detection in tissue samples?

For effective RPL17 localization in tissue sections:

• Fixation considerations:

  • Paraformaldehyde (4%) fixation preserves epitope accessibility

  • Optimize fixation duration to prevent overfixation which may mask epitopes

  • Consider retrieval methods based on antibody specifications

• Antigen retrieval optimization:

  • Test both heat-induced (citrate or EDTA buffer) and enzymatic retrieval methods

  • Optimize pH conditions (typically pH 6.0-9.0) based on epitope characteristics

  • Determine optimal retrieval duration to maximize signal while preserving tissue integrity

• Background reduction strategies:

  • Include appropriate blocking with serum matching secondary antibody species

  • Pre-absorb antibodies if cross-reactivity is observed

  • Optimize washing steps with appropriate detergent concentrations

• Signal detection methods:

  • For chromogenic detection, optimize DAB development time

  • For fluorescent detection, select fluorophores avoiding tissue autofluorescence

  • Consider signal amplification systems for low-abundance detection

What approaches can resolve contradictory results in RPL17 expression or function studies?

When facing discrepancies in RPL17 research findings:

• Antibody validation reassessment:

  • Verify antibody specificity using knockout/knockdown controls

  • Compare results with multiple antibodies targeting different epitopes

  • Confirm recognition of the correct molecular weight band (21-24 kDa)

• Experimental model considerations:

  • Account for species-specific differences in RPL17 function and expression

  • Consider cell type variations (e.g., expression differences between pancreatic tumor cell lines)

  • Evaluate disease state impact (normal vs. pathological conditions)

• Technical parameter adjustment:

  • Standardize protein extraction methods to ensure consistent ribosomal protein recovery

  • Normalize quantification using appropriate reference genes or total protein

  • Control for cell cycle stage and proliferation rates when comparing expression levels

• Integrative analysis approaches:

  • Combine antibody-based detection with mRNA quantification

  • Correlate protein expression with functional assays (e.g., proliferation, ribosome biogenesis)

  • Employ systems biology approaches to place contradictory findings in broader cellular context

How can RPL17 antibodies contribute to cancer research?

RPL17 antibodies offer valuable tools for investigating potential connections between ribosomal proteins and cancer biology:

• Expression profiling: RPL17 shows variable expression across pancreatic tumor cell lines, with high levels in well-differentiated lines (HPAF, COLO 357, Capan-1) and moderate expression in poorly differentiated lines (HCG-25, PANC-1) .

• Growth regulation studies: Given RPL17's role as a growth inhibitor in vascular smooth muscle cells, antibodies can help explore whether similar mechanisms operate in cancer contexts .

• Ribosome heterogeneity investigation: Antibodies can help determine if cancer cells exhibit altered ribosome composition affecting translational output.

• Therapeutic target validation: As RPL17 functions as a growth inhibitor, antibodies can monitor expression changes following experimental therapeutics aimed at restoring or enhancing its activity.

• Biomarker development: Correlation of RPL17 expression patterns with clinical outcomes could establish its potential as a prognostic or predictive biomarker.

What technological advances might enhance RPL17 antibody applications in future research?

Emerging technologies promise to expand RPL17 antibody applications:

• Single-cell antibody-based technologies: Application of RPL17 antibodies in single-cell Western blotting or mass cytometry can reveal cell-to-cell variability in expression.

• Super-resolution microscopy: Enhanced visualization of RPL17 subcellular localization beyond the diffraction limit may reveal previously undetected functional compartmentalization.

• Proximity labeling approaches: Combining RPL17 antibodies with BioID or APEX2 systems can map the protein's interaction networks in living cells.

• CRISPR-based epitope tagging: Endogenous tagging of RPL17 enables live-cell imaging and circumvents potential artifacts from antibody cross-reactivity.

• Spatial transcriptomics integration: Correlating RPL17 protein localization with spatially resolved transcriptome data may reveal local translation regulation mechanisms.

The continued development of these technologies, coupled with increasingly specific RPL17 antibodies, will further illuminate the multifaceted roles of this ribosomal protein in normal cellular function and disease contexts.

How can I address non-specific binding when using RPL17 antibodies?

Non-specific binding challenges can be resolved through systematic optimization:

• Blocking optimization:

  • Test different blocking agents (BSA, casein, normal serum)

  • Increase blocking duration or concentration

  • Consider commercial blocking solutions specifically designed to reduce background

• Antibody dilution adjustment:

  • Perform titration experiments to identify optimal concentration

  • For polyclonal antibodies like DF3699, higher dilutions may reduce non-specific binding

  • Consider pre-absorption with known cross-reactive proteins

• Wash protocol enhancement:

  • Increase wash duration and number of washes

  • Optimize detergent concentration in wash buffers

  • Use continuous agitation during washing steps

• Sample preparation refinement:

  • Ensure complete protein denaturation for Western blot applications

  • For tissue sections, optimize fixation and antigen retrieval methods

  • Consider using purified subcellular fractions to reduce background

• Alternative antibody selection:

  • Compare multiple RPL17 antibodies targeting different epitopes

  • Consider monoclonal antibodies for higher specificity in certain applications

  • Evaluate affinity-purified options like ABIN653848 which undergoes protein A column purification followed by peptide affinity purification